Key Segmentation
By Treatment Type
-
First-line Immunotherapy (Steroids, IVIG & Plasma Exchange)
-
B-cell Targeted Therapy (Rituximab)
-
Immunosuppressant
-
Emerging Biologics & FcRn/Cytokine Therapies
-
Others
By Diagnostic Method
-
Autoantibody Testing (Serum & CSF)
-
MRI & Neuroimaging
-
EEG
-
CSF Analysis & Biomarkers
-
Others
By Disease Type
-
Anti-NMDA Receptor Encephalitis
-
LGI1 Encephalitis
-
CASPR2 Encephalitis
-
Paraneoplastic Autoimmune Encephalitis
-
Others
By End User
-
Hospitals
-
Neurology Specialty Centers
-
Academic & Research Institutes
-
Diagnostic Laboratories
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
First-line Immunotherapy (Steroids, IVIG & Plasma Exchange) dominated the market, accounting for 46.00% of total revenue in 2025.
The market is expected to expand at a CAGR of 8.61% during the forecast period.
North America dominated the global market in 2025, accounting for 43.00% of total revenue.
The Autoimmune Encephalitis Treatment & Diagnostics Market was valued at USD 1.82 Billion in 2025.